Efficacy and Safety of Ustekinumab in Patients With Moderate to Severe Palmar Plantar Psoriasis
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Tufts Medical Center
- Study ID
- NCT01090063
- Status
- Completed
Conditions
- Moderate to Severe Palmar Plantar Psoriasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 85 Years
- Healthy Volunteers
- Not accepted
Interventions
- Ustekinumab — DRUGDosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
Study Details
The purpose of this study is to determine the short and long term safety and effectiveness of ustekinumab in subjects with moderate to severe chronic palmar plantar psoriasis.
Key Dates
- Start date
- Feb 28, 2010
- Status verified
- Sep 2016
- Primary completion
- Feb 29, 2012
- Completion
- Apr 30, 2012
Study Design
- Enrollment
- 26 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Percentage of Patients Achieving a Palmar/Plantar PGA Score of 0 or 1 at Week 16. [ Time Frame: 16 weeks ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Tufts Medical Center | Boston | Massachusetts | 02111 | - |
Find similar trials in Boston, MA
By research site